Category Press Releases

Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com

Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com The global cannabis pharmaceuticals market, valued at USD 3.46 billion in 2023, is expected to experience remarkable growth, reaching USD 380.77 billion by 2034. This expansion is forecasted…

Read MoreCannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com

Salubris Biotherapeutics Reports Positive Interim Data from Phase 2 Heart Failure Trial of JK07

Salubris Biotherapeutics Announces Positive Interim Data from Phase 2 Trial of JK07 in Heart Failure Salubris Biotherapeutics a clinical-stage biotechnology company focused on developing innovative biologic therapies, has announced promising interim data from its Phase 2 clinical trial of JK07…

Read MoreSalubris Biotherapeutics Reports Positive Interim Data from Phase 2 Heart Failure Trial of JK07

Poxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan

Poxel Achieves Milestone with TWYMEEG® Sales in Japan, Secures Royalties and Sales-Based Payments Poxel, a clinical-stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology—including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders—has announced a significant…

Read MorePoxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan

MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available

MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available Otsuka Pharmaceutical and Ai-BrainScience Inc. have announced the launch of MIREVO®, a pioneering neuropsychological testing program designed to support medical treatment for dementia. As of January 1, 2025, MIREVO® has…

Read MoreMIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available

Pharma Partners Gilead and LEO Pharma to Accelerate Oral STAT6 Program for Inflammatory Diseases

Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership designed to accelerate the development and commercialization of LEO Pharma’s…

Read MorePharma Partners Gilead and LEO Pharma to Accelerate Oral STAT6 Program for Inflammatory Diseases

Pharmaceutical Supply Chain Initiative Proudly Welcomes WuXi AppTec as Strategic Partner

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative to Strengthen Responsible Practices and Supply Chain Resilience Pharmaceutical Supply WuXi AppTec, a global leader providing comprehensive research, development, and manufacturing services to the pharmaceutical and life sciences industries, has announced its…

Read MorePharmaceutical Supply Chain Initiative Proudly Welcomes WuXi AppTec as Strategic Partner

Ailux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics

Ailux Biologics UCB\u2019s Strategic Collaboration with Ailux Biologics Ailux Biologics UCB, a leading global biopharmaceutical company, and XtalPi, an industry pioneer in AI-powered drug discovery, have announced a landmark license agreement involving XtalFold™, an advanced biologics AI platform. Developed by…

Read MoreAilux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics